NCT04717635 - Study of Efficacy and Safety of Canakinumab in Japanese Patients With AOSD | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 30, 2021

Primary Completion Date

April 16, 2025

Study Completion Date

April 16, 2025

Conditions

Adult Onset Still's Disease

Interventions

BIOLOGICAL

Canakinumab

Provide as 150 mg/1 mL solution for subcutaneous injection and administer 4mg/kg every 4 weeks.

Trial Locations (9)

Novartis Investigative Site, Chiba

Novartis Investigative Site, Sapporo

Novartis Investigative Site, Kanazawa

Novartis Investigative Site, Yokohama

Novartis Investigative Site, Iruma-gun

Novartis Investigative Site, Bunkyo Ku

Novartis Investigative Site, Chuo Ku

Novartis Investigative Site, Mitaka

Novartis Investigative Site, Shinjuku-ku